Table 3.
Comorbidities in ICU and treatments of patients with severe COVID-19.
| Characteristics | All patients (n = 45) | Intubated (n = 20) | Not intubated (n = 25) |
|---|---|---|---|
| APACHE II score | 14.0 (8.0–18.0) | 18.0 (15.0–24.8) | 10.0 (7.0–13.0) |
| SOFA score | 4.0 (3.0–6.8) | 6.0 (5.0–11.0) | 3.0 (2.0–3.8) |
| Comorbidities in ICU, n (%) | |||
| ARDS | 36 (80) | 20 (100) | 16 (64) |
| Mild, P/F ratio (mm Hg) | 250 (218–256) (n = 5) | 218 (n = 1) | 253 (238–257) (n = 4) |
| Moderate | 126 (105–163) (n = 22) | 115 (105–127) (n = 10) | 149 (112–180) (n = 12) |
| Severe | 90 (81–94) (n = 9) | 90 (81–94) (n = 9) | 0 |
| Septic shock | 15 (33.3) | 15 (75) | 0 |
| Cardiac injury | 15 (33.3) | 13 (65) | 2 (8) |
| Acute kidney injury | 8 (17.8) | 8 (40) | 0 |
| Transaminitis | 28 (62.2) | 16 (80) | 12 (48) |
| Gastrointestinal hemorrhage | 14 (31.1) | 12 (60) | 2 (8) |
| Barotrauma | 4 (8.9) | 4 (20) | 0 |
| Bacterial coinfection | 19 (42.2) | 15 (75) | 4 (16) |
| Fungal coinfection | 18 (40) | 11 (55) | 7 (28) |
| Treatment in ICU, n (%) | |||
| Antiviral agents | 45 (100) | 20 (100) | 25 (100) |
| Antibacterial agents | 45 (100) | 20 (100) | 25 (100) |
| Antifungal agents | 19 (42.2) | 14 (70) | 5 (20) |
| Convalescent plasma | 6 (13.3) | 6 (30) | 0 |
| Glucocorticoids | 28 (62.2) | 13 (65) | 15 (60) |
| Immunoglobulin | 28 (62.2) | 15 (75) | 13 (52) |
| Albumin | 35 (77.8) | 18 (90) | 17 (68) |
P/F ratio was available at ICU admission.